Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310241106> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4310241106 abstract "Advanced and metastatic RET-driven solid cancer is not susceptible to chemotherapy or radiotherapy. The development of targeted therapy has led to a new therapeutic model. Nevertheless, no systematic evaluation of their efficacy and safety has been carried out in RET-driven solid cancer. Systematic review and single-arm meta-analysis were performed. Four electronic databases were searched (PubMed, Embase, Cochrane Library, and Web of Science) from each database’s inception date until February 27, 2022. Study inclusion criteria focused on peer-reviewed published articles that reported the efficacy and safety of targeted therapy Inhibitors for RET-driven Solid Cancer, excluding case reports/series, review papers, meta-analyses, organizational guidelines, editorial letters, expert opinions, and conference abstracts. 15 randomized, locally advanced or metastatic RET-driven solid cancer assays (n=1835) were included. Previously untreated with RET-Specific Tyrosine Kinase Inhibitors(TKI) group showed the highest objective remission rate(ORR) (0.75,95%CI=0.68-0.82) or disease control rate(DCR) (0.96,95%CI=0.92-0.99), and lower dose reduction(34.8%) or discontinuation(3.4%), but the performance of general adverse reactions (Grade1-5 96.8%, Grade3-5 69.2%) were not as good as Multi-Target Tyrosine Kinase Inhibitors (MKI) group, followed by previously treated/untreated with MKI/TKI group (MIX group). Targeted therapy inhibitors have significant efficacy in RET-driven solid cancer therapy. The ORR, DCR parameters and adverse reaction of TKI are better than those of MKI. It was also related to the patient’s previous treatment status. The ORR/DCR of the patients who received no targeted therapy was superior to those who received Vandetanib or Cabozantinib as first-line therapy." @default.
- W4310241106 created "2022-11-30" @default.
- W4310241106 creator A5005893871 @default.
- W4310241106 creator A5014719345 @default.
- W4310241106 creator A5037985532 @default.
- W4310241106 creator A5062547589 @default.
- W4310241106 creator A5071318790 @default.
- W4310241106 date "2022-11-29" @default.
- W4310241106 modified "2023-09-24" @default.
- W4310241106 title "Efficacy and Safety of targeted therapy Inhibitors for RET-driven Solid Cancer: A Systematic Review and Meta-analysis" @default.
- W4310241106 doi "https://doi.org/10.22541/au.166971966.65533901/v1" @default.
- W4310241106 hasPublicationYear "2022" @default.
- W4310241106 type Work @default.
- W4310241106 citedByCount "0" @default.
- W4310241106 crossrefType "posted-content" @default.
- W4310241106 hasAuthorship W4310241106A5005893871 @default.
- W4310241106 hasAuthorship W4310241106A5014719345 @default.
- W4310241106 hasAuthorship W4310241106A5037985532 @default.
- W4310241106 hasAuthorship W4310241106A5062547589 @default.
- W4310241106 hasAuthorship W4310241106A5071318790 @default.
- W4310241106 hasBestOaLocation W43102411061 @default.
- W4310241106 hasConcept C121608353 @default.
- W4310241106 hasConcept C126322002 @default.
- W4310241106 hasConcept C143998085 @default.
- W4310241106 hasConcept C17744445 @default.
- W4310241106 hasConcept C189708586 @default.
- W4310241106 hasConcept C197934379 @default.
- W4310241106 hasConcept C199539241 @default.
- W4310241106 hasConcept C2776478404 @default.
- W4310241106 hasConcept C2778715236 @default.
- W4310241106 hasConcept C2778822529 @default.
- W4310241106 hasConcept C2779134260 @default.
- W4310241106 hasConcept C2779473830 @default.
- W4310241106 hasConcept C2779984678 @default.
- W4310241106 hasConcept C2781230642 @default.
- W4310241106 hasConcept C509974204 @default.
- W4310241106 hasConcept C71924100 @default.
- W4310241106 hasConcept C95190672 @default.
- W4310241106 hasConceptScore W4310241106C121608353 @default.
- W4310241106 hasConceptScore W4310241106C126322002 @default.
- W4310241106 hasConceptScore W4310241106C143998085 @default.
- W4310241106 hasConceptScore W4310241106C17744445 @default.
- W4310241106 hasConceptScore W4310241106C189708586 @default.
- W4310241106 hasConceptScore W4310241106C197934379 @default.
- W4310241106 hasConceptScore W4310241106C199539241 @default.
- W4310241106 hasConceptScore W4310241106C2776478404 @default.
- W4310241106 hasConceptScore W4310241106C2778715236 @default.
- W4310241106 hasConceptScore W4310241106C2778822529 @default.
- W4310241106 hasConceptScore W4310241106C2779134260 @default.
- W4310241106 hasConceptScore W4310241106C2779473830 @default.
- W4310241106 hasConceptScore W4310241106C2779984678 @default.
- W4310241106 hasConceptScore W4310241106C2781230642 @default.
- W4310241106 hasConceptScore W4310241106C509974204 @default.
- W4310241106 hasConceptScore W4310241106C71924100 @default.
- W4310241106 hasConceptScore W4310241106C95190672 @default.
- W4310241106 hasLocation W43102411061 @default.
- W4310241106 hasOpenAccess W4310241106 @default.
- W4310241106 hasPrimaryLocation W43102411061 @default.
- W4310241106 hasRelatedWork W3027459656 @default.
- W4310241106 hasRelatedWork W3082854370 @default.
- W4310241106 hasRelatedWork W3117110396 @default.
- W4310241106 hasRelatedWork W3134414398 @default.
- W4310241106 hasRelatedWork W4207082034 @default.
- W4310241106 hasRelatedWork W4226154391 @default.
- W4310241106 hasRelatedWork W4226383011 @default.
- W4310241106 hasRelatedWork W4289667130 @default.
- W4310241106 hasRelatedWork W4313625070 @default.
- W4310241106 hasRelatedWork W4315436681 @default.
- W4310241106 isParatext "false" @default.
- W4310241106 isRetracted "false" @default.
- W4310241106 workType "article" @default.